Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV24 in children aged 2-17 years
NCT06550830Phase 1Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sinovac PCV24 in pneumococcal infection (3 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Incidence of adverse reactions at 30 days. Started Sep 2024; status: completed.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06550830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550830.